Here's Why AbbVie's Stock Tanked in January

Unlike the vast majority of biopharma stocks, AbbVie's (NYSE: ABBV) stock actually lost ground in January. The drugmaker's shares, in fact, fell by an unsightly 12.9% during the first month of the new year, according to data from S&P Global Market Intelligence.